Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.46

-0.18 (-0.49%)

19:32
12/14/17
12/14
19:32
12/14/17
19:32

Pfizer announces FDA approval of Xeljanz

Pfizer announced that the FDA has approved Xeljanz 5 mg twice daily and Xeljanz XR extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis, or PSA, who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs. Xeljanz/Xeljanz XR is the first and only Janus kinase inhibitor approved by the FDA for both moderate to severe rheumatoid arthritis and active PsA. The FDA approval of Xeljanz for the treatment of adult patients with active PSA was based on data from the Phase 3 Oral Psoriatic Arthritis Trial, or OPAL, clinical development program, which consisted of two pivotal studies, OPAL Broaden and OPAL Beyond, as well as available data from an ongoing long-term extension trial, OPAL Balance.

  • 04

    Jan

PFE Pfizer
$36.46

-0.18 (-0.49%)

11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

RCI

Rogers Communications

$50.94

0.45 (0.89%)

07:10
07/19/18
07/19
07:10
07/19/18
07:10
Hot Stocks
Rogers Communications reports strong subscriber performance in Wireless in Q2 »

Reports: Service revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

07:10
07/19/18
07/19
07:10
07/19/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.19

-0.02 (-1.65%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Hot Stocks
Paramount Gold Nevada receives approval for fifth baseline data report »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$82.16

-0.17 (-0.21%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Earnings
Philip Morris lowers FY18 EPS view to $5.02-$5.12, consensus $5.15 »

Had seen FY18 EPS of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

GDX

Market Vector Gold Miners

$21.88

(0.00%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$131.69

0.98 (0.75%)

, EADSY

Airbus

$0.00

(0.00%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Hot Stocks
CALC orders Pratt & Whitney GTF engines for Airbus A320neo aircraft »

Pratt & Whitney, a…

UTX

United Technologies

$131.69

0.98 (0.75%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

FUL

H.B. Fuller

$55.97

0.58 (1.05%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Conference/Events
H.B. Fuller to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

RCI

Rogers Communications

$50.94

0.45 (0.89%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Earnings
Rogers Communications reports Q2 EPS C$1.07, consensus C$1.05 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$116.28

-0.005 (-0.00%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$157.49

-0.33 (-0.21%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Earnings
Pool Corp. narrows FY18 EPS view to $5.50-$5.70 from $5.45-$5.70 »

Consensus is $5.56. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

IBM

IBM

$144.44

0.98 (0.68%)

07:07
07/19/18
07/19
07:07
07/19/18
07:07
Recommendations
IBM analyst commentary  »

IBM price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

NUGT

Direxion Gold Miners Bull

$23.05

0.02 (0.09%)

07:07
07/19/18
07/19
07:07
07/19/18
07:07
Technical Analysis
Direxion Gold Miners Bull: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$157.49

-0.33 (-0.21%)

07:06
07/19/18
07/19
07:06
07/19/18
07:06
Earnings
Pool Corp. reports Q2 EPS $2.80, consensus $2.88 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

TRV

Travelers

$130.03

1.26 (0.98%)

07:06
07/19/18
07/19
07:06
07/19/18
07:06
Hot Stocks
Travelers sees catastrophe losses highest in Q2 »

"Turning to weather…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$13.08

0.18 (1.40%)

07:06
07/19/18
07/19
07:06
07/19/18
07:06
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTS

Tile Shop

$8.30

0.2 (2.47%)

07:06
07/19/18
07/19
07:06
07/19/18
07:06
Hot Stocks
Tile Shop sees FY18 capital investment of approx. $32M »

The Company updated its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

BX

Blackstone

$36.23

0.52 (1.46%)

07:05
07/19/18
07/19
07:05
07/19/18
07:05
Earnings
Blackstone reports Q2 ENI 90c, consensus 75c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.56

0.04 (0.16%)

07:05
07/19/18
07/19
07:05
07/19/18
07:05
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXRX

Concordia

$0.00

(0.00%)

07:05
07/19/18
07/19
07:05
07/19/18
07:05
Hot Stocks
Concordia delisting from NASDAQ »

Concordia received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$4.14

0.08 (1.97%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Upgrade
Meet Group rating change  »

Meet Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$52.46

-0.51 (-0.96%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Technical Analysis
Daily Junior Gold Miners Index Bear 3x Shares: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

$42.51

0.03 (0.07%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Earnings
Sandy Spring Bancorp reports Q2 EPS 73c ex-items, consensus 76c »

Total loans increased 51%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 14

    Aug

  • 12

    Sep

TTS

Tile Shop

$8.30

0.2 (2.47%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Earnings
Tile Shop reports Q2 EPS 10c, consensus 8c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

BMY

Bristol-Myers

$56.88

0.24 (0.42%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Hot Stocks
Bristol-Myers announces research collaboration with Gritstone Oncology »

Bristol-Myers and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$26.77

0.46 (1.75%)

, SQ

Square

$68.30

-0.02 (-0.03%)

07:04
07/19/18
07/19
07:04
07/19/18
07:04
Recommendations
PagSeguro Digital, Square analyst commentary  »

Deutsche sees PagSeguro…

PAGS

PagSeguro Digital

$26.77

0.46 (1.75%)

SQ

Square

$68.30

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

  • 31

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.